



RealRate

MEDICINAL PRODUCTS 2022











**MEDICINAL PRODUCTS 2022** 



BALCHEM CORP Rank 8 of 51



The relative strengths and weaknesses of BALCHEM CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BALCHEM CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 61% points. The greatest weakness of BALCHEM CORP is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 110%, being 124% points above the market average of -14%.

| Input Variable                     | Value in<br>1000 USD |
|------------------------------------|----------------------|
| Assets, Current                    | 322,232              |
| Assets, Non-Current                | 18,603               |
| General and Administrative Expense | 657,997              |
| Goodwill                           | 618,614              |
| Liabilities, Current               | 190,257              |
| Liabilities, Non-Current           | 4,811                |
| Other Assets                       | 2,359                |
| Other Compr. Net Income            | -9,166               |
| Other Expenses                     | 29,129               |
| Other Liabilities                  | 127,242              |
| Other Net Income                   | -2,269               |
| Other Revenues                     | 799,023              |
| Property, Plant and Equipment, Net | 237,517              |
| Research and Development           | 13,524               |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Liabilities              | 322,310              |
| Assets                   | 1,199,325            |
| Expenses                 | 700,650              |
| Revenues                 | 799,023              |
| Stockholders Equity      | 877,015              |
| Net Income               | 96,104               |
| Comprehensive Net Income | 91,521               |
| Economic Capital Ratio   | 110%                 |

